LGALS3BP has anti-tumor activity in colon cancer by suppressing Wnt signaling (Piccolo et al, 2015) and also plays a role in preventing and treating inflammatory diseases by suppressing TAK1-dependent NF-κB activation (Hong et al, 2019). Here, NFKB1 is linked to colonic neoplasm.